management of hypertension and hyperlipidemia in hematopoietic cell transplant (hct) patients joseph...
TRANSCRIPT
![Page 1: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/1.jpg)
Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients
Joseph Bubalo PharmD, BCPS, BCOP
Oncology Clinical Pharmacy Specialist
OHSU Hospital & Clinics
![Page 2: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/2.jpg)
Objectives
• Discuss the unique needs of blood pressure and lipid management in the HCT population
• Review selection and individualization of the different therapeutic options available for managing hypertension and hyperlipidemia
![Page 3: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/3.jpg)
Patient Case • AA is a 27 year old male s/p a sibling donor
HCT for his AML. He is currently day +125 and doing well. His recent cyclosporine taper was interrupted due to GVHD of the skin and bowel which have responded to treatment with prednisone and continuation of his cyclosporine at therapeutic levels.
• His blood pressure has been slowly creeping up and today is 155/91.
![Page 4: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/4.jpg)
Prevalence of Cardiac Risk
• Autologous and allogeneic HCT experience higher mortality rates and 2.3 x the risk of cardiovascular (CV) death in adults – Similar reports for pediatrics
• Higher rates of CV risk factors– Increased triglycerides (TG)– Decreased high-density lipoproteins (HDL)– Hypertension– Hyperglycemia (fasting)– Increased waist circumference
Baker KS et al BMT 2012;47:619-25
![Page 5: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/5.jpg)
Hypertension• Reported in 21-63% of patients
• Solid organ transplant reports 65-100% incidence
• Calcineurin inhibitors most likely cause– Cyclosporine (CSA) worse than tacrolimus (FK)– Sirolimus and mycophenolate less likely to cause
hypertension– Corticosteroids mixed effects
• At 2 years post transplant hypertension resolved in 2/3 of patient in one report
Majhail NS, et al BBMT 2009;15:1100-07
![Page 6: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/6.jpg)
Metabolic Syndrome
• Insulin resistance – Primary driver– Also central obesity, glucose intolerance, dyslipidemia,
hypertension, – Common among HCT survivors– Lead to Type II diabetes mellitus (DM) & atherosclerotic
CV disease
• Contribution of HCT related procedures and complications still unclear– TBI, high dose chemotherapy, calcineurin inhibitors,
corticosteroids, GVHD, etc
Baker KS et al BMT 2012;47:619-25
![Page 7: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/7.jpg)
Screening
Screen (condition) Interval/test
Blood pressure (hypertension) Measure at every healthcare episode
Fasting Lipids (dyslipidemia) Every 2 years if hypertension or hypercholesterolemia, every 5 years if not
EKG/echocardiogram (cardiomyopathy)
2 years after completing therapy then every 1-5 years depending on treatment exposures
Fasting glucose (impaired glucose tolerance/diabetes)
Every 2 years
Baker KS et al BMT 2012;47:619-25
![Page 8: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/8.jpg)
• Given the well documented increased cardiovascular risks of people post-HCT the next steps in the evolution of care is to identify those at risk early and to implement interventions to modify those risks or disease defining events
Chow EJ et al Annals Internal Medicine 2011;155:21-32
![Page 9: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/9.jpg)
Issues/Risk factors
• Older age and cardiovascular disease, esp. arterial
• Co-morbidities at time of HCT– Traditional risk factors (obesity, inactivity,
smoking, etc) do not change
• Allogeneic increased hypertension over autologous
Baker KS et al Blood 2007;109(4): 1765-72 Tichelli A, et al Haematologica 2008;93(8):1203-10
![Page 10: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/10.jpg)
Special patient groups
• Highest risk patients– Diabetes– Abdominal aortic aneurysm– Carotid stenosis– Peripheral arterial disease
![Page 11: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/11.jpg)
Treating Hypertension
• Hypertension – Systolic > 140 and/or diastolic > 90– Diabetics: systolic > 130 and/or diastolic > 80
• Calcineurin inhibitor (CI) -induced hypertension– Secondary to renal vasoconstriction and sodium
retention
• Corticosteroids – sodium retention
• Other causes
![Page 12: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/12.jpg)
Treating Hypertension
• Dihydropyridine calcium channel blockers– Amlodipine, nifedipine (XL only), felodipine, NO
nicardipine– Verapamil, diltiazem not preferred but may be
useful for cardiac arrhythmias
• Reverses acute vasoconstriction, may limit CI nephrotoxicity through preferential dilatation of afferent arteriole
• Rare cases of increased CSA levels
![Page 13: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/13.jpg)
Hypertension in NPO patients
• Intravenous acute care options– Hydralazine – Metoprolol
• Topical– Clonidine
NPO – no oral intake
![Page 14: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/14.jpg)
Alternate Antihypertensives• Beta blockers – for patients with prior CV history, monitor
heart rate• Angiotensin converting enzyme inhibitors (ACE) inhibitors –
drug of choice in diabetics, increased risk for nephrotoxicity, hyperkalemia
• Angiotensin receptor blockers (ARB) – alternate to ACE inhibitors. Less nephrotoxic?
• Diuretics
• May be preferred depending on co-morbidities
![Page 15: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/15.jpg)
Antihypertensive Dosing
Drug Starting dose Maximum
Amlodipine 2.5-5 mg daily 10 mg daily
Felodipine 2.5-5 mg daily 20 mg daily
Nifedipine XL 30 mg daily 180 mg daily
Hydralazine IV 5-10 mg Q 4-6 hours 20 mg q 6 hours
Metoprolol IV 2.5-5 mg Q 6-8 hours 10 mg Q 6 hours
Clonidine (topical) 0.1 mg daily 0.3 mg daily
![Page 16: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/16.jpg)
Treating hyperlipidemia
• Low density lipoproteins (LDL) primary target (treat if > 100)– HDL and TG secondary (treat <40 or >500)
• Lifestyle modifications– Decreased saturated fats and cholesterol– Increased plant stanols/sterols and viscous fiber
to lower LDL – Weight control and exercise
Circulation 2002;106:3143-3421
![Page 17: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/17.jpg)
Drug causes of hyperlipidemia• Glucocorticoids
– affect metabolic pathways increasing weight, blood glucose, lipids
• Cyclosporine– Inhibit bile acid synthesis, block LDL receptor
• Tacrolimus– Less lipid effects than CSA
• Sirolimus, everolimus– Increase triglycerides and lipids
![Page 18: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/18.jpg)
Hyperlipidemia Treatment
• LDL predominant– Statins– Bile acid binders– Cholesterol absorption inhibitors
• Hypertriglyceridemia– Omega 3 fatty acids– Niacin– Fibrates
![Page 19: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/19.jpg)
Statins
• Not 3A4 metabolizedPreferred
– Fluvastatin 20-80 mg
– Pravastatin 10-80 mg
– Rosuvastatin 5-40 mg
• 3A4 metabolized– Atorvastatin 10-80 mg
– Lovastatin 20-80 mg
– Simvastatin 20-80 mg
• Avoid use if on azole
• Decrease LDL and TG, Increase HDL• Monitor transaminases, myositis, rhabdomyolysis
![Page 20: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/20.jpg)
Bile Acid Binders
• Decrease LDL 15-30%• Colesevelam 3750 mg daily – preferred
– Can dose as once or twice daily– Dose several hours away from other drugs– Monitor drug levels (CSA, FK)
• Less absorption issues vs. colestipol or cholestyramine
• Do not use if high TG
![Page 21: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/21.jpg)
Cholesterol Absorption Inhibitors
• Ezetimibe– Decrease LDL~15%– 10 mg daily– Less potent than statins– Second line agent
• Do not stop but usually not a lot of value to starting it
![Page 22: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/22.jpg)
Hypertriglyceridemia
• Statins – decrease 7-30%, helpful in mild disease (<500)
• Niacin - decrease 30-40%– Use ER dose forms to improve tolerance– Good choice if LDL high as well– No drug interactions– AE: flushing, GI intolerance, increase glucose,
uric acid
![Page 23: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/23.jpg)
Hypertriglyceridemia
• Omega 3 fatty acids - decrease 35-45%– 2-4 gm daily in 2 doses– Decrease hepatic production of TG– Impair platelet aggregation
• Doses > 3 gm/day
– GI upset, diarrhea
![Page 24: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/24.jpg)
Hypertriglyceridemia
• Fibrates - decrease 20-50%
• Use if > 500 mg/dl– Gemfibrozil 600-1200 mg daily, in 2 doses– Fenofibrate 45-200 mg daily – preferred
• AE: cholelithiasis, GI upset, myopathy – increased with statins
• Caution in renal impairment
![Page 25: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/25.jpg)
Monitoring• Obtain fasting lipid profile pre-transplant
– Start therapy if indicated
• Post HSCT– Repeat fasting lipid profile 4-8 weeks post
transplant then every 3 months if on immunosuppression
• Stable patient at goal, check every 6-12 months• Patient without dyslipidemia every 1-2 years
Griffiths ML et al Blood 2010;116(8):1197-1204
![Page 26: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/26.jpg)
Monitoring
• Challenging in acute care setting post HSCT– Effects of TPN
• Intermittent lipids can give false results
– GI chemo toxicity or GVHD may affect med selection and efficacy/absorption
– Increased drug interaction issues
• Long term follow up clinic more predictable results
![Page 27: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/27.jpg)
Patient Case AA
• Antihypertensive?
• Fasting lipid panel, then follow up
• Diet intervention vs. medication if indicated
• Individual patient issues that need to be considered
• Availability for follow-up
![Page 28: Management of Hypertension and Hyperlipidemia in Hematopoietic Cell Transplant (HCT) patients Joseph Bubalo PharmD, BCPS, BCOP Oncology Clinical Pharmacy](https://reader036.vdocuments.mx/reader036/viewer/2022062314/56649e045503460f94aefa85/html5/thumbnails/28.jpg)
Summary• Management issues
– Adherence– Side effects:– Cost– Monitoring
• Drug interactions• Success – in general population <30% have both
hypertension and high cholesterol controlled, since ATPIII < 20% success with dyslipidemia control
Egan BM et al Circulation 2013;128:29-41